Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | NPY4R | P50391 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16979030 | 0.79 | SLC6A4 (0.49) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL11248115 | 0.77 | SLC6A4 (0.47) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL4598274 | 0.77 | SLC6A4 (0.47) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL744402 | 0.77 | SLC6A4 (0.47) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL19144912 | 0.76 | IDO1 (0.64) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| Iodide SCHEMBL744206 | 0.76 | SLC6A4 (0.46) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL3137822 | 0.74 | EPHX1 (0.53) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL6347241 | 0.73 | SLC6A4 (0.43) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL18253219 | 0.73 | DHODH (0.42) | SLC6A4SLC6A2NPY1RNPY2RNPY4R | |
| SCHEMBL5877391 | 0.73 | TSHR (0.38) | SLC6A4SLC6A2HSD11B1NPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828364-B2 | Pyrazole compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-28 | — | — | US | disclosed |
| US-9828364-B2 | Pyrazole compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-28 | — | — | US | disclosed |
| US-20160340339-A1 | PYRAZOLE COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-20160340339-A1 | PYRAZOLE COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340339-A1 | PYRAZOLE COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | SLC6A4 4832/4885IDO1 592/4885SLC6A2 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.